Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly & Co. stock underperforms Thursday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 5,745.37 and the Dow Jones Industrial Average DJIA rising 0.62% to 42,175.11.
Eli Lilly And Co (LLY) Stock: Beyond the Surface of Its Performance?
On Thursday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $909.32 which represents a decrease of $-15.24 or -1.65% from the prior close of $924.56. The stock opened at $920.26 and touched a low of $905.
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 598.51% and currently trading at $923.50. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Is Eli Lilly Stock Still a Buy Near All-Time Highs?
Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in August. With the shares up nearly 68% in the past 52 weeks and 58.5% year-to-date,
23h
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
But Lilly isn't alone in the market, and in the coming years, this space could become more crowded. Today, Lilly competes ...
2d
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
3d
on MSN
Eli Lilly's Alzheimer's drug approved in Japan
Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...
1d
Eli Lilly’s EBGLYSS offers long-term disease control in atopic dermatitis trial
Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...
1d
Investigation Discloses Safety, Efficacy Concerns About Eli Lilly's Donanemab
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
6d
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
9d
Eli Lilly urges court to toss $183 mln Medicaid fraud judgment
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
3d
on MSN
Eli Lilly’s Alzheimer’s treatment Kisunla wins approval in Japan
Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...
3d
Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...
17h
Novo faces ‘Nokia risk’ as it fights Lilly’s homecourt advantage
The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Japan
Trade
Food and Drug Administration
Kisunla
Novo Nordisk
Feedback